2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-124958
    NDMC101 1308631-40-4 99.91%
    NDMC101 is a potent osteoclastogenesis inhibitor and inhibits osteoclast differentiation via down-regulation of NFATc1-modulated gene expression. NDMC101 is similar to the DPP4 substrate and is a significant inhibitor of early T-cell activation via DPP4 inhibition. NDMC101can be used for study of bone disorders, such as rheumatoid arthritis, and synovial inflammation et al.
    NDMC101
  • HY-124996
    (Rac)-ZLc-002 98.96%
    (Rac)-ZLc-002, an inhibitor of nNOS interaction with nitric oxide synthase 1 adaptor protein (NOS1AP), suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with Paclitaxel (HY-B0015) to reduce tumor cell viability.
    (Rac)-ZLc-002
  • HY-125025
    SMI 6860766 433234-16-3 98%
    SMI 6860766, a small molecule inhibitor of CD40-TRAF6 interaction, improves glucose tolerance, reduces immune cell accumulation in adipose tissue, and reduces AT inflammation.
    SMI 6860766
  • HY-125096
    C108297 864972-30-5 99.97%
    C108297 is a selective glucocorticoid receptor (GR) modulator (GR binding Ki 0.7 nM; GR reporter gene functional Ki 0.6 nM). C108297 attenuates obesity by reducing caloric intake and increasing lipolysis and fat oxidation, and in addition attenuates inflammation.
    C108297
  • HY-125415
    PF-4693627 1312815-93-2 99.63%
    PF-4693627 is a potent, selective and orally bioavailable microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor (IC50=3 nM) for the treatment of inflammation caused by osteoarthritis (OA) and rheumatoid arthritis (RA).
    PF-4693627
  • HY-125654
    Olanexidine 146510-36-3 98%
    Olanexidine is an antibacterial agent. Olanexidine is active against a wide range of bacteria, imcluding both Gram-positive and Gram-negative bacteria Olanexidine is also an antiseptic. Olanexidine can be used in the research of infection and inflammation.
    Olanexidine
  • HY-125770
    5(S)​-​HPETE 71774-08-8 ≥98.0%
    5(S)-HPETE is a 5-lipoxygenase substrate and Arachidonic acid (HY-109590) metabolite. 5(S)-HPETE forms via 5-LOX-catalyzed hydroperoxidation of arachidonic acid. 5(S)-HPETE undergoes 5-LOX-catalyzed epoxidation (dehydration) to form leukotriene A4. 5(S)-HPETE can be used for the research of asthma, rheumatoid arthritis.
    5(S)​-​HPETE
  • HY-125975
    1-Naphthyl 3,5-dinitrobenzoate 93261-39-3 99.49%
    1-Naphthyl 3,5-dinitrobenzoate is a potent 5-lipoxygenase inhibitor with IC50 values of 1.04 µM and 3.6 µM for 5-LOX and mPGES-1, respectively. 1-Naphthyl 3,5-dinitrobenzoate has strong inhibition activity in the human whole blood (HWB) assay with an IC50 value of 8.6 μM. 1-Naphthyl 3,5-dinitrobenzoate can be used in research of inflammation.
    1-Naphthyl 3,5-dinitrobenzoate
  • HY-126134
    HPGDS inhibitor 2 2101626-26-8 99.72%
    HPGDS inhibitor 2 is a highly potent and selective hematopoietic prostaglandin D synthase (H-PGDS) inhibitor with an IC50 of 9.9 nM.
    HPGDS inhibitor 2
  • HY-126361
    ZK824190 2254001-81-3 98%
    ZK824190 is an orally available and selective urokinase plasminogen activator (uPA) inhibitor as a potential treatment for multiple sclerosis. IC50s of 237, 1600 and 1850 nM for uPA, tPA, and Plasmin, respectively.
    ZK824190
  • HY-126479
    Carbomycin B 21238-30-2 98%
    Carbomycin B is a macrolide antibiotic.
    Carbomycin B
  • HY-12752S
    Alimemazine-d6 1346603-88-0 99.55%
    Alimemazine-d6 is deuterium labeled Alimemazine, which is an antihistamine.
    Alimemazine-d6
  • HY-12785S
    Albendazole sulfoxide D3 1448346-38-0 99.79%
    Albendazole sulfoxide-d3 is deuterium labeled Albendazole sulfoxide, which is a broad-spectrum anthelmintic.
    Albendazole sulfoxide D3
  • HY-128449
    Cephradine monohydrate 75975-70-1
    Cephradine (Cefradine) monohydrate is a broad-spectrum and orally active cephalosporin. Cephradine monohydrate is active against both grampositive and gram-negative pathogens and effective in eradicating most penicillinase-producing organisms known to be resistant to penicillin G, penicillin V, and ampicillin. Cephradine monohydrate has been used in the research of genitourinary, gastrointestinal and respiratory tract infections, and in infections of the skin and soft tissues. Cephradine monohydrate blocks solar-ultraviolet induced skin inflammation through direct inhibition of TOPK.
    Cephradine monohydrate
  • HY-128703
    Bromodomain inhibitor-8 1300031-70-2 98.02%
    Bromodomain inhibitor-8 (example 1) is a BET bromodomain inhibitor for treating autoimmune and inflammatory diseases.
    Bromodomain inhibitor-8
  • HY-129151
    Ganoderic acid C1 95311-97-0
    Ganoderic acid C1, a natural compound that could be isolated from G. lucidum, suppresses TNF-α production by murine macrophages (RAW 264.7 cells).
    Ganoderic acid C1
  • HY-129529
    6-Hydroxyluteolin 7-glucoside 54300-65-1 99.25%
    6-Hydroxyluteolin 7-glucoside is a glycoside. 6-Hydroxyluteolin 7-glucoside can be isolated from Tanacetum vulgare and C. chrvsanthus cv. Cream Beauty. 6-Hydroxyluteolin 7-glucoside can be used in inflammation research.
    6-Hydroxyluteolin 7-glucoside
  • HY-12974A
    PRT-060318 dihydrochloride 3032567-93-1 98.98%
    PRT-060318 (PRT318) dihydrochloride is a potent, selective and orally active tyrosine kinase Syk inhibitor with an IC50 of 3 nM. PRT-060318 dihydrochloride suppresses chronic lymphocytic leukemia (CLL) B cell activation and migration, and induces apoptosis. PRT-060318 dihydrochloride prevents Heparin (HY-17567)-induced thrombocytopenia and thrombosis in a transgenic mouse model. PRT-060318 dihydrochloride can be used for CLL and thrombus research.
    PRT-060318 dihydrochloride
  • HY-130150
    m-PEG5-succinimidyl carbonate 1058691-00-1 98.0%
    m-PEG5-succinimidyl carbonate is a non-cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG5-succinimidyl carbonate is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs.
    m-PEG5-succinimidyl carbonate
  • HY-130288
    (±)13-HDHA 90780-53-3 98.8%
    (±)13-HDHA is an autoxidation product of docosahexaenoic acid (DHA) in vitro. It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes. Fresh water hydra is shown to metabolize DHA to 13(R)-HDHA, presumably via the 11R-lipoxygenase activity. (±)13-HDHA is a potential marker of oxidative stress in brain and retina where DHA is an abundant polyunsaturated fatty acid.
    (±)13-HDHA
Cat. No. Product Name / Synonyms Application Reactivity